Thyrocare Technologies Limited reported a 62% year-on-year increase in profit after tax (PAT) to ₹38.06 crore for the quarter ended June 30, 2025. The company's revenue from operations grew by 23% to ₹193.03 crore.
| Metric | Q1 FY26 | Q1 FY25 | YoY Change | FY25 |
|---|---|---|---|---|
| Revenue from operations | 193.03 | 156.91 | +23% | 687.32 |
| Gross margin | 137.40 | 111.46 | +23% | 496.25 |
| Normalized EBITDA (before ESOP) | 63.35 | 44.73 | +42% | 209.94 |
| Reported EBITDA | 57.46 | 42.01 | +37% | 189.21 |
| Profit after tax incl. exceptional item | 38.06 | 23.47 | +62% | 90.02 |
| Gross margin% | 71% | 71% | 72% | |
| Normalized EBITDA% | 33% | 29% | 31% | |
| Reported EBITDA% | 30% | 27% | 28% | |
| PAT incl. exceptional item% | 20% | 15% | 13% |
Financial Performance
Thyrocare's consolidated revenue for Q1FY26 saw a YoY increase of 23%, driven by a 25% growth in Pathology and a 6% growth in Radiology. The Pathology business experienced a 20% YoY growth in franchise revenue and a 36% YoY surge in partnership revenue.
Operational Highlights
The total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase. The company's consolidated gross margin stood at 71%, with a reported EBITDA margin of 30%.
Expansion
Thyrocare opened new labs in Bhagalpur, Kashmir, and Roorkee during the quarter.
About Thyrocare
Thyrocare Technologies Limited is an advanced, fully automated laboratory chain with a strong presence across India, focusing on providing quality and affordable diagnostic services to laboratories and hospitals. As of Q1FY26, Thyrocare has over 9,500 active franchises and processed over 46.9 million diagnostic and screening investigations.
